Past Meeting | Keystone Symposia

This meeting took place in the past. Here is a list of meetings that are related:
	Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit (2019C2)
Cancer Immunotherapy: Combinations (2018C5)
Emerging Cellular Therapies: T Cells and Beyond (2018B6)
Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology (2017C7)
Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies (2016J6)
Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (2015J7)

Web Desc
Cancer Immunology and Immunotherapy joint with Antibodies as Drugs Organizer(s): Glenn Dranoff, Carl H. June and Suzanne L. Topalian Date: January 27 - February 01, 2013 Location: Fairmont Hotel Vancouver, Vancouver, BC, Canada Sponsored by Bayer USA Foundation and Bristol-Myers Squibb Company. Supported by an educational donation provided by Amgen. Summary of Meeting: The recent FDA approvals of Provenge® as the first therapeutic cancer vaccine and Ipilimumab® as the first monoclonal antibody that blocks negative immune regulation are landmark achievements that highlight substantive progress in cancer immunology. These novel treatments derive from the cumulative insights of basic and translational scientists into the mechanisms of protective tumor immunity in cancer patients. Advances in genetic, cellular and biochemical technologies have dramatically increased our understanding of the pathways through which the host responds to cancer. Tumor-host interactions in the microenvironment are increasingly recognized to play a critical role in determining disease inhibition or promotion. This Keystone Symposia meeting will bring together leading cancer immunologists to discuss their most recent insights into immune recognition, regulation, tumor escape and therapeutic manipulation. Emerging areas of cancer metabolism and material science engineering that relate to cancer immunology will be highlighted. The integration of basic and clinical aspects of tumor immunity in this meeting should stimulate interest from a wide array of investigators and students. The concurrent meeting on Antibodies as Drugs will underscore the increasing connections between these fields, and potentially accelerate the development of new cancer immunotherapies. Scholarship Deadline: September 25 2012 Discounted Abstract Deadline: September 25 2012 Abstract Deadline: October 25 2012 Discounted Registration Deadline: November 27 2012 Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting: We gratefully acknowledge additional support for this conference from: Ono Pharmaceutical Co. Ltd. We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements: Immunocore Limited Micromet, Inc. $1 - $2,499 Cancer Immunity Molecular Metabolism (Elsevier GmbH) We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: Click here to view more of these organizations Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds: Click here to view more of these organizations

Web Desc

Cancer Immunology and Immunotherapy

joint with Antibodies as Drugs

Organizer(s): Glenn Dranoff, Carl H. June and Suzanne L. Topalian

Date: January 27 - February 01, 2013
Location: Fairmont Hotel Vancouver, Vancouver, BC, Canada

Sponsored by Bayer USA Foundation and Bristol-Myers Squibb Company. Supported by an educational donation provided by Amgen.

Summary of Meeting:

The recent FDA approvals of Provenge® as the first therapeutic cancer vaccine and Ipilimumab® as the first monoclonal antibody that blocks negative immune regulation are landmark achievements that highlight substantive progress in cancer immunology. These novel treatments derive from the cumulative insights of basic and translational scientists into the mechanisms of protective tumor immunity in cancer patients. Advances in genetic, cellular and biochemical technologies have dramatically increased our understanding of the pathways through which the host responds to cancer. Tumor-host interactions in the microenvironment are increasingly recognized to play a critical role in determining disease inhibition or promotion. This Keystone Symposia meeting will bring together leading cancer immunologists to discuss their most recent insights into immune recognition, regulation, tumor escape and therapeutic manipulation. Emerging areas of cancer metabolism and material science engineering that relate to cancer immunology will be highlighted. The integration of basic and clinical aspects of tumor immunity in this meeting should stimulate interest from a wide array of investigators and students. The concurrent meeting on Antibodies as Drugs will underscore the increasing connections between these fields, and potentially accelerate the development of new cancer immunotherapies.

Scholarship Deadline: September 25 2012

Discounted Abstract Deadline: September 25 2012

Abstract Deadline: October 25 2012

Discounted Registration Deadline: November 27 2012

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional support for this conference from:

Ono Pharmaceutical Co. Ltd.

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Immunocore Limited

Micromet, Inc.

$1 - $2,499

Cancer Immunity

Molecular Metabolism (Elsevier GmbH)

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program


Sunday, January 27 \| 3:00PM - 7:30PM Arrival and Registration Room: British/Columbia Foyer
Sunday, January 27 \| 6:15PM - 7:15PM Refreshments Room: British/Columbia Foyer
Sunday, January 27 \| 7:15PM - 8:30PM Welcome and Keynote Address Room: Columbia Ballroom Speaker 1 of 2 * Glenn Dranoff, Novartis Institutes for BioMedical Research, USA
Sunday, January 27 \| 7:15PM - 8:30PM Welcome and Keynote Address Room: Columbia Ballroom Speaker 2 of 2 James P. Allison, University of Texas MD Anderson Cancer Center, USA Checkpoint Blockade
Monday, January 28 \| 6:45AM - 8:00AM Breakfast Room: Pacific Ballroom
Monday, January 28 \| 8:00AM - 11:00AM Tumor Targeting - From Understanding Mechanisms to New Targe ting Agents (Joint) Room: British/Columbia Ballroom Speaker 1 of 6 * Dario Neri, ETH Zürich, Switzerland
Monday, January 28 \| 8:00AM - 11:00AM Tumor Targeting - From Understanding Mechanisms to New Targe ting Agents (Joint) Room: British/Columbia Ballroom Speaker 2 of 6 Karl Dane Wittrup, Massachusetts Institute of Technology, USA Synergistic Antibody and Cytokine Effects in Cancer Immunotherapy
Monday, January 28 \| 8:00AM - 11:00AM Tumor Targeting - From Understanding Mechanisms to New Targe ting Agents (Joint) Room: British/Columbia Ballroom Speaker 3 of 6 Kerry A. Chester, University College London Cancer Institute, UK Antibody-Targeted Nanoparticles for Cancer Treatment
Monday, January 28 \| 8:00AM - 11:00AM Tumor Targeting - From Understanding Mechanisms to New Targe ting Agents (Joint) Room: British/Columbia Ballroom Speaker 4 of 6 Erkki Ruoslahti, Sanford-Burnham Medical Research Institute, USA Increasing Extravasation with Peptides
Monday, January 28 \| 8:00AM - 11:00AM Tumor Targeting - From Understanding Mechanisms to New Targe ting Agents (Joint) Room: British/Columbia Ballroom Speaker 5 of 6 Anna M. Wu, University of California, Los Angeles, USA Engineered Antibodies for Molecular Imaging of Cancer
Monday, January 28 \| 8:00AM - 11:00AM Tumor Targeting - From Understanding Mechanisms to New Targe ting Agents (Joint) Room: British/Columbia Ballroom Speaker 6 of 6 Henry B. Lowman, CytomX, USA Short Talk: Probody™ Therapeutics: A New Class of Proteolytically Activated Antibodies
Monday, January 28 \| 9:20AM - 9:40AM Coffee Break Room: British/Columbia Foyer
Monday, January 28 \| 10:00AM - 10:00AM On Own for Lunch and Recreation
Monday, January 28 \| 11:00AM - 1:00PM Poster Setup Room: Pacific Ballroom
Monday, January 28 \| 1:00PM - 10:00PM Poster Viewing Room: Pacific Ballroom
Monday, January 28 \| 2:30PM - 4:30PM Workshop 1: Emerging Antibody Generation Methods This session is from Antibodies as Drugs Room: British Ballroom Speaker 1 of 8 * James D. Marks, University of California, San Francisco, USA
Monday, January 28 \| 2:30PM - 4:30PM Workshop 1: Emerging Antibody Generation Methods This session is from Antibodies as Drugs Room: British Ballroom Speaker 2 of 8 Filippa Fleetwood, Royal Institute of Technology, Sweden Surface Display of a Single-Domain Antibody Library on Gram-Positive Bacteria
Monday, January 28 \| 2:30PM - 4:30PM Workshop 1: Emerging Antibody Generation Methods This session is from Antibodies as Drugs Room: British Ballroom Speaker 3 of 8 Christian Kunz, MorphoSys AG, Germany The Role of HuCAL in the Discovery of Lead Antibodies with a Unique MoA
Monday, January 28 \| 2:30PM - 4:30PM Workshop 1: Emerging Antibody Generation Methods This session is from Antibodies as Drugs Room: British Ballroom Speaker 4 of 8 Audrey D. McConnell, AnaptysBio, Inc., USA High Affinity Humanized Antibodies without Making Hybridomas; Immunization Paired with Mammalian Cell Display and in vitro Somatic Hypermutation
Monday, January 28 \| 2:30PM - 4:30PM Workshop 1: Emerging Antibody Generation Methods This session is from Antibodies as Drugs Room: British Ballroom Speaker 5 of 8 Amandeep K. Gakhal, Sutro Biopharma, USA A New Method for Direct Selection of Synthetic Antibody Fragments on Cell Surface Targets from a Phage-Displayed Library
Monday, January 28 \| 2:30PM - 4:30PM Workshop 1: Emerging Antibody Generation Methods This session is from Antibodies as Drugs Room: British Ballroom Speaker 6 of 8 E-Chiang Lee, Kymab, UK Development of a Next-Generation in vivo mAb Discovery Platform
Monday, January 28 \| 2:30PM - 4:30PM Workshop 1: Emerging Antibody Generation Methods This session is from Antibodies as Drugs Room: British Ballroom Speaker 7 of 8 Hiroshi Hamana, University of Toyama, Japan Rabbit ISSAC (Rabbit Immunospot Array Assay on a Chip) Allows for the Rapid Generation of Rabbit Monoclonal Antibodies with High Affinity
Monday, January 28 \| 2:30PM - 4:30PM Workshop 1: Emerging Antibody Generation Methods This session is from Antibodies as Drugs Room: British Ballroom Speaker 8 of 8 Kai Zhu, Schrodinger Inc., USA Ab initio Structure Prediction of the Antibody Hypervariable H3 Loop
Monday, January 28 \| 4:30PM - 5:00PM Coffee Available Room: British/Columbia Foyer
Monday, January 28 \| 5:00PM - 7:00PM Tumor Microenvironment Room: Columbia Ballroom Speaker 1 of 5 * James P. Allison, University of Texas MD Anderson Cancer Center, USA
Monday, January 28 \| 5:00PM - 7:00PM Tumor Microenvironment Room: Columbia Ballroom Speaker 2 of 5 Wolf-Hervé Fridman, Cordeliers Research Centre, France The Immune Microenvironment of Primary and Metastatic Human Tumors
Monday, January 28 \| 5:00PM - 7:00PM Tumor Microenvironment Room: Columbia Ballroom Speaker 3 of 5 Robert D. Schreiber, Washington University School of Medicine, USA Cancer Immunoediting: Antigens, Mechanisms and Implications for Cancer Immunotherapy
Monday, January 28 \| 5:00PM - 7:00PM Tumor Microenvironment Room: Columbia Ballroom Speaker 4 of 5 Nikhil S. Joshi, Yale University School of Medicine, USA Short Talk: Effector Regulatory T Cell Differentiation during Autochthonous Mouse Lung Adenocarcinoma Development
Monday, January 28 \| 5:00PM - 7:00PM Tumor Microenvironment Room: Columbia Ballroom Speaker 5 of 5 Drew M. Pardoll, Johns Hopkins University School of Medicine, USA Inflammation and Cancer
Monday, January 28 \| 5:00PM - 7:00PM Payloaded Antibodies for Cancer Treatment This session is from Antibodies as Drugs Room: British Ballroom Speaker 1 of 4 * Peter D. Senter, Seattle Genetics Inc., USA Empowered Antibodies for Cancer Therapy
Monday, January 28 \| 5:00PM - 7:00PM Payloaded Antibodies for Cancer Treatment This session is from Antibodies as Drugs Room: British Ballroom Speaker 2 of 4 Dario Neri, ETH Zürich, Switzerland Armed Antibodies for Vascular Targeting
Monday, January 28 \| 5:00PM - 7:00PM Payloaded Antibodies for Cancer Treatment This session is from Antibodies as Drugs Room: British Ballroom Speaker 3 of 4 Paul G. Polakis, Genentech, Inc., USA Antibody Drug Conjugates for the Treatment of Cancer
Monday, January 28 \| 5:00PM - 7:00PM Payloaded Antibodies for Cancer Treatment This session is from Antibodies as Drugs Room: British Ballroom Speaker 4 of 4 Brian J. Agnew, Thermo Fisher Scientific, USA Short Talk: Site-Selective Antibody Labeling without Engineering: Answering Unmet Needs in Antibody Payload Conjugation
Monday, January 28 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Pacific Ballroom
Monday, January 28 \| 7:30PM - 10:00PM Poster Session 1 Room: Pacific Ballroom
Tuesday, January 29 \| 6:45AM - 8:00AM Breakfast Room: Pacific Ballroom
Tuesday, January 29 \| 8:00AM - 11:15AM Engineering and Immunotherapy Room: Columbia Ballroom Speaker 1 of 7 * Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA
Tuesday, January 29 \| 8:00AM - 11:15AM Engineering and Immunotherapy Room: Columbia Ballroom Speaker 2 of 7 David J. Mooney, Harvard University, USA Polymer Scaffolds for immunotherapy
Tuesday, January 29 \| 8:00AM - 11:15AM Engineering and Immunotherapy Room: Columbia Ballroom Speaker 3 of 7 Darrell J. Irvine, Massachusetts Institute of Technology, USA Interfacing Nanoparticle Drug Carriers with Lymphocytes to Enhance Cellular Immunotherapy
Tuesday, January 29 \| 8:00AM - 11:15AM Engineering and Immunotherapy Room: Columbia Ballroom Speaker 4 of 7 Carl H. June, University of Pennsylvania, USA Engineered T Cells for Adoptive Therapy
Tuesday, January 29 \| 8:00AM - 11:15AM Engineering and Immunotherapy Room: Columbia Ballroom Speaker 5 of 7 Hollie J. Jackson, Memorial Sloan Ketter Cancer Center, USA Short Talk: Expansion and Modification of Umbilical Cord Blood T Cells with a Chimeric Antigen Receptor and IL-12
Tuesday, January 29 \| 8:00AM - 11:15AM Engineering and Immunotherapy Room: Columbia Ballroom Speaker 6 of 7 Sheena N. Smith, University of Zurich, Switzerland Short Talk: Engineering Designer T Cell Receptors through the Use of Single-Chain T Cell Receptor Scaffolds
Tuesday, January 29 \| 8:00AM - 11:15AM Engineering and Immunotherapy Room: Columbia Ballroom Speaker 7 of 7 Laurence J. N. Cooper, ZIOPHARM Oncology, Inc., USA Sleeping Beauty Transposition for Engineered T Cells
Tuesday, January 29 \| 8:00AM - 11:15AM Antibodies in Infectious Diseases This session is from Antibodies as Drugs Room: British Ballroom Speaker 1 of 5 Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland Human Antibodies to Infectious Disease Targets
Tuesday, January 29 \| 8:00AM - 11:15AM Antibodies in Infectious Diseases This session is from Antibodies as Drugs Room: British Ballroom Speaker 2 of 5 * Dennis R. Burton, The Scripps Research Institute, USA Broadly Neutralizing Antibodies to Identify Vaccine Targets on HIV
Tuesday, January 29 \| 8:00AM - 11:15AM Antibodies in Infectious Diseases This session is from Antibodies as Drugs Room: British Ballroom Speaker 3 of 5 Gary J. Nabel, Sanofi, USA Broadly Neutralizing Antibodies to HIV: A Model for Prevention and Treatment of an Infectious Disease
Tuesday, January 29 \| 8:00AM - 11:15AM Antibodies in Infectious Diseases This session is from Antibodies as Drugs Room: British Ballroom Speaker 4 of 5 Erica Ollmann Saphire, La Jolla Institute for Immunology, USA Antibodies Against the Filoviruses
Tuesday, January 29 \| 8:00AM - 11:15AM Antibodies in Infectious Diseases This session is from Antibodies as Drugs Room: British Ballroom Speaker 5 of 5 George Georgiou, University of Texas at Austin, USA Proteomic Deconvolution of the Human Serological IgG Repertoire in Vaccine Evaluation and Antibody Discovery
Tuesday, January 29 \| 9:20AM - 9:40AM Coffee Break Room: British/Columbia Foyer
Tuesday, January 29 \| 10:00AM - 10:00AM On Own for Lunch and Recreation
Tuesday, January 29 \| 11:15AM - 1:00PM Poster Setup Room: Pacific Ballroom
Tuesday, January 29 \| 1:00PM - 10:00PM Poster Viewing Room: Pacific Ballroom
Tuesday, January 29 \| 4:30PM - 5:00PM Coffee Available Room: British/Columbia Foyer
Tuesday, January 29 \| 5:00PM - 7:00PM Cancer Vaccines Room: Columbia Ballroom Speaker 1 of 5 * Carl H. June, University of Pennsylvania, USA
Tuesday, January 29 \| 5:00PM - 7:00PM Cancer Vaccines Room: Columbia Ballroom Speaker 2 of 5 Cornelia Liu Trimble, Johns Hopkins University School of Medicine, USA Tissue T Cells in HPV Disease
Tuesday, January 29 \| 5:00PM - 7:00PM Cancer Vaccines Room: Columbia Ballroom Speaker 3 of 5 Cornelis J. M. Melief, Leiden University Medical Center & ISA Pharmaceuticals BV, Netherlands Chemo-Immunotherapy of High Risk HPV Infections
Tuesday, January 29 \| 5:00PM - 7:00PM Cancer Vaccines Room: Columbia Ballroom Speaker 4 of 5 Marieke Griffioen, Leiden University Medical Center, Netherlands Short Talk: Intercellular Transfer of Natural HLA Class II Ligands Is Mediated by Full Length Proteins with Abundant Cellular Expression that Are Sequestered and Secreted into Microvesicles
Tuesday, January 29 \| 5:00PM - 7:00PM Cancer Vaccines Room: Columbia Ballroom Speaker 5 of 5 David H. Kirn, Jennerex, USA Targeted Oncolytic and Immunotherapeutic Viruses: Emerging Multi-Mechanistic Biologics for Cancer
Tuesday, January 29 \| 5:00PM - 7:00PM New Technologies for Generating Proteins with Novel Function s This session is from Antibodies as Drugs Room: British Ballroom Speaker 1 of 5 * Andreas G. Plückthun, University of Zürich, Switzerland
Tuesday, January 29 \| 5:00PM - 7:00PM New Technologies for Generating Proteins with Novel Function s This session is from Antibodies as Drugs Room: British Ballroom Speaker 2 of 5 David Baker, University of Washington, USA Computational Protein Design and Protein Therapeutics
Tuesday, January 29 \| 5:00PM - 7:00PM New Technologies for Generating Proteins with Novel Function s This session is from Antibodies as Drugs Room: British Ballroom Speaker 3 of 5 Andrew D. Ellington, University of Texas at Austin, USA Rational Engineering of Antibodies for Affinity and Stability
Tuesday, January 29 \| 5:00PM - 7:00PM New Technologies for Generating Proteins with Novel Function s This session is from Antibodies as Drugs Room: British Ballroom Speaker 4 of 5 Julia Shifman, Hebrew University of Jerusalem, Israel Computational Design of Protein-Protein Interactions
Tuesday, January 29 \| 5:00PM - 7:00PM New Technologies for Generating Proteins with Novel Function s This session is from Antibodies as Drugs Room: British Ballroom Speaker 5 of 5 Romain Rouet, University of California, Berkeley, USA Short Talk: Stability Engineering of Human Antibody Therapeutics
Tuesday, January 29 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Pacific Ballroom
Tuesday, January 29 \| 7:30PM - 10:00PM Poster Session 2 Room: Pacific Ballroom
Wednesday, January 30 \| 6:45AM - 8:00AM Breakfast Room: Pacific Ballroom
Wednesday, January 30 \| 7:30AM - 8:00AM Poster Setup Room: Pacific Ballroom
Wednesday, January 30 \| 8:00AM - 5:00PM Poster Viewing Room: Pacific Ballroom
Wednesday, January 30 \| 8:00AM - 11:15AM Adoptive Cellular Therapy Room: Columbia Ballroom Speaker 1 of 7 * Laurence Zitvogel, Institut Gustave Roussy, France
Wednesday, January 30 \| 8:00AM - 11:15AM Adoptive Cellular Therapy Room: Columbia Ballroom Speaker 2 of 7 Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA Chimeric Antigen Receptor Design and T Cell Subsets in Adoptive Therapy
Wednesday, January 30 \| 8:00AM - 11:15AM Adoptive Cellular Therapy Room: Columbia Ballroom Speaker 3 of 7 Kazuhiro Kakimi, University of Tokyo Hospital, Japan Short Talk: Autologous gammadelta T Cell Transfer Therapy for the Treatment of Solid Cancer
Wednesday, January 30 \| 8:00AM - 11:15AM Adoptive Cellular Therapy Room: Columbia Ballroom Speaker 4 of 7 Nicholas P. Restifo, Lyell, USA Memory T Cells Precede Effector Cells: Why it Matters for ACT
Wednesday, January 30 \| 8:00AM - 11:15AM Adoptive Cellular Therapy Room: Columbia Ballroom Speaker 5 of 7 Catherine M. Bollard, Children’s National Health System, USA T Cell Therapies for EBV+ Lymphomas – Where Have We Come From and Where Are We Going?
Wednesday, January 30 \| 8:00AM - 11:15AM Adoptive Cellular Therapy Room: Columbia Ballroom Speaker 6 of 7 Yanxia Guo, Bristol-Myers Squibb, USA Short Talk: Retinoic Acid-Rich Microenvironment Provides Clonal Survival Cues for Tumor and Bacteria-Specific CD8+ T Cells
Wednesday, January 30 \| 8:00AM - 11:15AM Adoptive Cellular Therapy Room: Columbia Ballroom Speaker 7 of 7 Robert S. Negrin, Stanford University, USA Immunobiology of Allogeneic Hematopoietic Cell Transplantation
Wednesday, January 30 \| 8:00AM - 11:00AM Modulating the Activity of Growth Factor Receptors This session is from Antibodies as Drugs Room: British Ballroom Speaker 1 of 6 * Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Wednesday, January 30 \| 8:00AM - 11:00AM Modulating the Activity of Growth Factor Receptors This session is from Antibodies as Drugs Room: British Ballroom Speaker 2 of 6 Ermanno Gherardi, University of Pavia, Italy Structure/Function and Therapeutic Targeting of HGF/SF and MET
Wednesday, January 30 \| 8:00AM - 11:00AM Modulating the Activity of Growth Factor Receptors This session is from Antibodies as Drugs Room: British Ballroom Speaker 3 of 6 Andreas G. Plückthun, University of Zürich, Switzerland Engineering Receptor Ligands for Powerful Cellular Responses
Wednesday, January 30 \| 8:00AM - 11:00AM Modulating the Activity of Growth Factor Receptors This session is from Antibodies as Drugs Room: British Ballroom Speaker 4 of 6 Yosef Yarden, Weizmann Institute of Science, Israel Antibodies to EGFR Family as Drugs
Wednesday, January 30 \| 8:00AM - 11:00AM Modulating the Activity of Growth Factor Receptors This session is from Antibodies as Drugs Room: British Ballroom Speaker 5 of 6 Carlos F. Barbas III, The Scripps Research Institute, USA Multifunctional and Multi-Specific Antibodies: Single-Protein Combination Therapeutics
Wednesday, January 30 \| 8:00AM - 11:00AM Modulating the Activity of Growth Factor Receptors This session is from Antibodies as Drugs Room: British Ballroom Speaker 6 of 6 Klaus Koefoed, Symphogen A/S, Denmark Short Talk: In vitro Comparison of EGFR/Her3 Targeting Antibody Mixtures and Bispecific MEHD7945A Analogue Shows More Efficacious Inhibition by Mixtures, Even Under Conditions Mimicking Cancer Resistance
Wednesday, January 30 \| 9:20AM - 9:40AM Coffee Break Room: British/Columbia Foyer
Wednesday, January 30 \| 11:15AM - 12:00PM Lunch Room: Pacific Ballroom
Wednesday, January 30 \| 12:00PM - 2:30PM Poster Session 3 Room: Pacific Ballroom
Wednesday, January 30 \| 2:30PM - 4:30PM Workshop: Advances in Cancer Immunology Room: Columbia Ballroom Speaker 1 of 7 * Wolf-Hervé Fridman, Cordeliers Research Centre, France
Wednesday, January 30 \| 2:30PM - 4:30PM Workshop: Advances in Cancer Immunology Room: Columbia Ballroom Speaker 2 of 7 Sally Amos, BC Cancer Agency, Canada Human Bilateral Breast Cancer: A Unique Opportunity to Examine Behaviors of Tumor-Infiltrating Lymphocytes
Wednesday, January 30 \| 2:30PM - 4:30PM Workshop: Advances in Cancer Immunology Room: Columbia Ballroom Speaker 3 of 7 Sarah Q. Crome, University Health Network, Canada Regulatory Natural Killer Cells Inhibit Anti-Tumour T Cells
Wednesday, January 30 \| 2:30PM - 4:30PM Workshop: Advances in Cancer Immunology Room: Columbia Ballroom Speaker 4 of 7 Connie Duong, Peter MacCallum Cancer Centre, Australia Generating Stronger T Cells for Adoptive Immunotherapy
Wednesday, January 30 \| 2:30PM - 4:30PM Workshop: Advances in Cancer Immunology Room: Columbia Ballroom Speaker 5 of 7 Daniel T. Fisher, Roswell Park Cancer Institute, USA Thermal Activation of IL-6 Trans-Signaling Licenses Mouse and Human Tumor Microvascular Gateways for Trafficking of Cytotoxic T Cells
Wednesday, January 30 \| 2:30PM - 4:30PM Workshop: Advances in Cancer Immunology Room: Columbia Ballroom Speaker 6 of 7 Richard P. Junghans, Roger Williams Hospital, USA Phase I Trial Data in Prostate Cancer Suggest Critical Role for IL2 Adjunctive Co-Therapy for Successful Suppression of Solid Tumor with Designer T Cells
Wednesday, January 30 \| 2:30PM - 4:30PM Workshop: Advances in Cancer Immunology Room: Columbia Ballroom Speaker 7 of 7 Brian Ruffell, Oregon Health & Science University, USA Macrophages Regulate Response to Chemotherapy in Mammary Carcinomas
Wednesday, January 30 \| 2:30PM - 4:30PM Workshop 2: Enhancing Effector Functions and Extending Half- Life This session is from Antibodies as Drugs Room: British Ballroom Speaker 1 of 6 * Henry B. Lowman, CytomX, USA
Wednesday, January 30 \| 2:30PM - 4:30PM Workshop 2: Enhancing Effector Functions and Extending Half- Life This session is from Antibodies as Drugs Room: British Ballroom Speaker 2 of 6 Javier Chaparro-Riggers, Rinat-Pfizer Inc., USA Improving PK and Cholesterol Lowering by a pH-Sensitive Anti-PCSK9-Antibody
Wednesday, January 30 \| 2:30PM - 4:30PM Workshop 2: Enhancing Effector Functions and Extending Half- Life This session is from Antibodies as Drugs Room: British Ballroom Speaker 3 of 6 Jonathan Sockolosky, University of California, San Francisco, USA Engineering FcRn-Mediated Recycling and Transcytosis in Recombinant Proteins by Short Terminal Peptide Extensions
Wednesday, January 30 \| 2:30PM - 4:30PM Workshop 2: Enhancing Effector Functions and Extending Half- Life This session is from Antibodies as Drugs Room: British Ballroom Speaker 4 of 6 Tomoyuki Igawa, Chugai Pharmabody Research, Singapore Engineered Antibody Fc Variant with Selectively Enhanced FcgammaRIIb Binding Over Both FcgammaRIIaR131 and FcgammaRIIaH131
Wednesday, January 30 \| 2:30PM - 4:30PM Workshop 2: Enhancing Effector Functions and Extending Half- Life This session is from Antibodies as Drugs Room: British Ballroom Speaker 5 of 6 Elizabeth L. Smith, University of California, Berkeley, USA Antibody Glycoengineering with Aldehyde Tag Technology
Wednesday, January 30 \| 2:30PM - 4:30PM Workshop 2: Enhancing Effector Functions and Extending Half- Life This session is from Antibodies as Drugs Room: British Ballroom Speaker 6 of 6 Surjit B. Dixit, Zymeworks Inc., Canada AlbuCORE™ – Structure-Guided Engineering and Design of a Multi-Valent Albumin Scaffold
Wednesday, January 30 \| 4:30PM - 5:00PM Coffee Available Room: British/Columbia Foyer
Wednesday, January 30 \| 5:00PM - 7:00PM Metabolism and Cancer Room: Columbia Ballroom Speaker 1 of 5 * Stanley R. Riddell, Fred Hutchinson Cancer Research Center, University of Washington, USA
Wednesday, January 30 \| 5:00PM - 7:00PM Metabolism and Cancer Room: Columbia Ballroom Speaker 2 of 5 Laurence Zitvogel, Institut Gustave Roussy, France Role of Type 1 IFN and dsRNA Sensors in the T Cell-Dependent Efficacy of Chemotherapy
Wednesday, January 30 \| 5:00PM - 7:00PM Metabolism and Cancer Room: Columbia Ballroom Speaker 3 of 5 Vincenzo Bronte, University of Verona, Italy Myeloid Derived Suppressor Cells
Wednesday, January 30 \| 5:00PM - 7:00PM Metabolism and Cancer Room: Columbia Ballroom Speaker 4 of 5 George C. Prendergast, Lankenau Institute for Medical Research, USA IDO Pathways and Targeting
Wednesday, January 30 \| 5:00PM - 7:00PM Metabolism and Cancer Room: Columbia Ballroom Speaker 5 of 5 Courtney Crane, University of Washington, USA Short Talk: Tumor Derived Lactate Dehydrogenase Drives Innate Immune Cell Crosstalk in Patients
Wednesday, January 30 \| 5:00PM - 7:15PM Bispecific and Multispecific Targeting Agents This session is from Antibodies as Drugs Room: British Ballroom Speaker 1 of 6 * Paul Carter, Genentech, Inc., USA
Wednesday, January 30 \| 5:00PM - 7:15PM Bispecific and Multispecific Targeting Agents This session is from Antibodies as Drugs Room: British Ballroom Speaker 2 of 6 Kaspar Binz, Molecular Partners, Switzerland Exploiting Novel Therapeutic Mechanisms Using Multi-Specific DARPins
Wednesday, January 30 \| 5:00PM - 7:15PM Bispecific and Multispecific Targeting Agents This session is from Antibodies as Drugs Room: British Ballroom Speaker 3 of 6 James D. Marks, University of California, San Francisco, USA Development and Mechanism of Action of mAb Combinations that Potently Neutralize Botlinum Neurotoxin
Wednesday, January 30 \| 5:00PM - 7:15PM Bispecific and Multispecific Targeting Agents This session is from Antibodies as Drugs Room: British Ballroom Speaker 4 of 6 Lutz Jermutus, MedImmune LLC, UK A Novel Multi-Mechanistic Monoclonal Antibody Format for Treating Pseudomonas aeruginosa Infections
Wednesday, January 30 \| 5:00PM - 7:15PM Bispecific and Multispecific Targeting Agents This session is from Antibodies as Drugs Room: British Ballroom Speaker 5 of 6 Janine Schuurman, Genmab B.V., Netherlands Short Talk: Efficient Generation of Stable Bispecific IgG1 by Controlled Fab-Arm Exchange
Wednesday, January 30 \| 5:00PM - 7:15PM Bispecific and Multispecific Targeting Agents This session is from Antibodies as Drugs Room: British Ballroom Speaker 6 of 6 David Poon, Zymeworks Inc., Canada Short Talk: Azymetric™ Scaffold – Optimized Fc Heterodimer for Improved Purity and Stability in the Development of Bispecific Antibodies
Wednesday, January 30 \| 7:00PM - 7:00PM On Own for Dinner
Thursday, January 31 \| 6:45AM - 8:00AM Breakfast Room: Pacific Ballroom
Thursday, January 31 \| 8:00AM - 11:15AM Immunomodulatory Antibody Therapies (Joint) Room: British/Columbia Ballroom Speaker 1 of 7 * George J. Weiner, University of Iowa, USA
Thursday, January 31 \| 8:00AM - 11:15AM Immunomodulatory Antibody Therapies (Joint) Room: British/Columbia Ballroom Speaker 2 of 7 Suzanne L. Topalian, Johns Hopkins University School of Medicine, USA PD-1 Blockade in Cancer Therapy
Thursday, January 31 \| 8:00AM - 11:15AM Immunomodulatory Antibody Therapies (Joint) Room: British/Columbia Ballroom Speaker 3 of 7 Li Wang, Medical College of Wisconsin, USA Short Talk: Targeting a Novel Immune Checkpoint Protein VISTA Alters Tumor Microenvironment and Synergizes with Cancer Vaccine to Eradicate Established Melanoma
Thursday, January 31 \| 8:00AM - 11:15AM Immunomodulatory Antibody Therapies (Joint) Room: British/Columbia Ballroom Speaker 4 of 7 Nils Lonberg, Canaan Partners, USA Development Hurdles for Immuno-Oncology Antibody Drugs
Thursday, January 31 \| 8:00AM - 11:15AM Immunomodulatory Antibody Therapies (Joint) Room: British/Columbia Ballroom Speaker 5 of 7 Johannes vom Berg, University of Zürich, Switzerland Short Talk: Local Interleukin-12 in Combination with Systemic Checkpoint Blockade Leads to T-Cell Dependent Rejection of Advanced Stage Glioma
Thursday, January 31 \| 8:00AM - 11:15AM Immunomodulatory Antibody Therapies (Joint) Room: British/Columbia Ballroom Speaker 6 of 7 Patrick A. Baeuerle, Amgen Research (Munich) GmbH, Germany Immunotherapy with BiTE® Antibodies: Lessons Learned from Blinatumomab
Thursday, January 31 \| 8:00AM - 11:15AM Immunomodulatory Antibody Therapies (Joint) Room: British/Columbia Ballroom Speaker 7 of 7 Bent Jakobsen, Immunocore Ltd., UK IMCgp100: A Bispecific TCR Anti-CD3 Fusion for the Treatment of Malignant Melanoma
Thursday, January 31 \| 9:30AM - 9:50AM Coffee Break Room: British/Columbia Foyer
Thursday, January 31 \| 10:00AM - 10:00AM On Own for Lunch and Recreation
Thursday, January 31 \| 4:30PM - 5:00PM Coffee Available Room: British/Columbia Foyer
Thursday, January 31 \| 5:00PM - 7:00PM Anti-Cancer Antibodies Room: Columbia Ballroom Speaker 1 of 5 * Nils Lonberg, Canaan Partners, USA
Thursday, January 31 \| 5:00PM - 7:00PM Anti-Cancer Antibodies Room: Columbia Ballroom Speaker 2 of 5 George J. Weiner, University of Iowa, USA Therapeutic Mechanisms of Monoclonal Antibodies
Thursday, January 31 \| 5:00PM - 7:00PM Anti-Cancer Antibodies Room: Columbia Ballroom Speaker 3 of 5 Timo K. van den Berg, Sanquin Blood Supply, Netherlands Short Talk: CD47-SIRPalpha Interactions Form a Barrier for Antibody-Mediated Tumor Cell Destruction by Phagocytes
Thursday, January 31 \| 5:00PM - 7:00PM Anti-Cancer Antibodies Room: Columbia Ballroom Speaker 4 of 5 Ronald P. DeMatteo, Memorial Sloan-Kettering Cancer Center, USA Combined Immunologic and Molecular Therapy for Cancer
Thursday, January 31 \| 5:00PM - 7:00PM Anti-Cancer Antibodies Room: Columbia Ballroom Speaker 5 of 5 Glenn Dranoff, Novartis Institutes for BioMedical Research, USA Therapy-Induced Antibody Responses
Thursday, January 31 \| 5:00PM - 7:00PM Challenges and New Opportunities with Antibody Drugs This session is from Antibodies as Drugs Room: British Ballroom Speaker 1 of 4 * Kerry A. Chester, University College London Cancer Institute, UK
Thursday, January 31 \| 5:00PM - 7:00PM Challenges and New Opportunities with Antibody Drugs This session is from Antibodies as Drugs Room: British Ballroom Speaker 2 of 4 Ryan J. Watts, Denali Therapeutics Inc, USA Engineering Bispecific Blood-Brain Barrier Crossing Antibodies
Thursday, January 31 \| 5:00PM - 7:00PM Challenges and New Opportunities with Antibody Drugs This session is from Antibodies as Drugs Room: British Ballroom Speaker 3 of 4 Leo James, MRC Laboratory of Molecular Biology, UK Intracellular Immunity and TRIM21
Thursday, January 31 \| 5:00PM - 7:00PM Challenges and New Opportunities with Antibody Drugs This session is from Antibodies as Drugs Room: British Ballroom Speaker 4 of 4 Sripad Ram, University of Texas Southwestern Medical Center, USA Short Talk: Multifocal Plane Microscopy Reveals Novel Intracellular Trafficking Pathways at the Blood-Brain Barrier with Implications to Antibody Delivery to the Brain
Thursday, January 31 \| 7:00PM - 8:00PM Social Hour with Lite Bites Room: Pacific Ballroom
Thursday, January 31 \| 8:00PM - 11:00PM Entertainment Room: Pacific Ballroom
Thursday, January 31 \| 8:00PM - 11:00PM Cash Bar Room: Pacific Ballroom
Friday, February 01 \| 10:25AM - 10:25AM Departure *Session Chair.